

## PRODUCT INFORMATION

|   |  |
|---|--|
| <b>Clone ID</b>                         | DMC275   |
| <b>Target</b>                           | ALB  |
| <b>Synonyms</b>                         | HSA; PRO0883; PRO0903; PRO1341   |
| <b>Host Species</b>                     | Rabbit   |
| <b>Description</b>                      | PE-conjugated Anti-ALB antibody(DMC275); IgG1 Chimeric mAb   |
| <b>Delivery</b>                         | Under Development  |
| <b>Uniprot ID</b>                       | P02768   |
| <b>IgG type</b>                         | Rabbit/Human Fc chimeric IgG1  |
| <b>Clonality</b>                        | Monoclonal   |
| <b>Reactivity</b>                       | Human  |
| <b>Applications</b>                     | Flow Cyt   |
| <b>Recommended Dilutions</b>            | Flow Cyt 1:100   |
| <b>Purification</b>                     | Purified from cell culture supernatant by affinity chromatography  |
| <b>Formulation &amp; Reconstitution</b> | Liquid□PBS with 0.05% Proclin300, 1% BSA   |
| <b>Storage &amp; Shipping</b>           | Store at 2°C-8°C for 6 months  |
| <b>Background</b>                       | This gene encodes the most abundant protein in human blood. This protein functions in the regulation of blood plasma colloid osmotic pressure and acts as a carrier protein for a wide range of endogenous molecules including hormones; fatty acids; and metabolites; as well as exogenous drugs. Additionally; this protein exhibits an esterase-like activity with broad substrate specificity. The encoded preproprotein is proteolytically processed to generate the mature protein. A peptide derived from this protein; EPI-X4; is an endogenous inhibitor of the CXCR4 chemokine receptor. |
| <b>Usage</b>                            | Research use only  |
| <b>Conjugate</b>                        | PE-conjugated  |
| <b>DIMA Disclaimer</b>                  | All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.   |

